Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY [NYSE]
Sanofi
Index- P/E26.13 EPS (ttm)1.87 Insider Own- Shs Outstand2.65B Perf Week-2.48%
Market Cap129.55B Forward P/E15.15 EPS next Y3.23 Insider Trans- Shs Float2.37B Perf Month6.10%
Income4.91B PEG4.62 EPS next Q- Inst Own10.20% Short Float0.10% Perf Quarter2.54%
Sales38.18B P/S3.39 EPS this Y20.30% Inst Trans3.63% Short Ratio0.97 Perf Half Y-11.50%
Book/sh24.26 P/B2.01 EPS next Y2.38% ROA5.80% Target Price55.00 Perf Year-1.65%
Cash/sh3.15 P/C15.53 EPS next 5Y5.65% ROE10.10% 52W Range43.57 - 57.42 Perf YTD7.13%
Dividend1.91 P/FCF- EPS past 5Y-3.70% ROI7.00% 52W High-15.71% Beta1.01
Dividend %3.91% Quick Ratio1.80 Sales past 5Y1.80% Gross Margin67.70% 52W Low11.09% ATR0.83
Employees112128 Current Ratio1.80 Sales Q/Q111.10% Oper. Margin19.10% RSI (14)50.29 Volatility1.12% 1.28%
OptionableYes Debt/Eq0.26 EPS Q/Q153.50% Profit Margin16.60% Rel Volume0.51 Prev Close48.86
ShortableYes LT Debt/Eq0.24 Earnings- Payout36.50% Avg Volume2.47M Price48.40
Recom1.70 SMA20-0.49% SMA503.06% SMA200-4.61% Volume1,105,582 Change-0.94%
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
Jun-14-07Downgrade JP Morgan Overweight → Neutral
Jun-14-07Downgrade HSBC Securities Overweight → Neutral
Mar-02-15 10:30AM  Looking for European Dividends? Say Oui to the France ETF ETF Trends
08:15AM  MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter at TheStreet
Feb-27-15 04:05PM  What structural reforms are required by different countries? Market Realist
02:38PM  Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog Zacks
12:10PM  Who Might Buy Puma Biotechnology? at Barrons.com
10:46AM  Oculus Innovative Sciences No One Trick Pony With Launch of New Animal Healthcare Division Company Spotlight
09:00AM  Afrezza's Initial Sales Create Buying Opportunity at Forbes
Feb-26-15 02:53PM  What You Should Know Before Watching Vice's Special About Curing Cancer at Forbes
10:15AM  MannKind: 'Encouraged By Early Feedback' on Afrezza Launch at Barrons.com
09:50AM  BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Zacks
Feb-25-15 10:18AM  MannKind: Nothing to See Here at Barrons.com
10:02AM  MannKind Reports Narrower Y/Y Loss in Q4, Afrezza in Focus - Analyst Blog Zacks
09:40AM  VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog Zacks
Feb-23-15 11:06AM  Big pharma invests big money in research and development Market Realist
Feb-20-15 03:10PM  Lysosomal Therapeutics to use $20M to develop, test Parkinson's drug at American City Business Journals
09:00AM  Afrezza Will Succeed But Initial Sales Likely To Disappoint at Forbes
08:30AM  FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Company Spotlight
08:06AM  Sales have been slower than expected. It takes time to educate the physician. Yahoo Finance Contributors
07:10AM  5 Tasks for Sanofi's New CEO at The Wall Street Journal
06:45AM  Genzyme's parent company names Bayer exec as its new CEO at American City Business Journals
Feb-19-15 04:56PM  Sanofi's new CEO CNBC
Feb-18-15 04:07PM  No, The New Cholesterol Drugs From Sanofi And Amgen Aren't Going To Cost $150 Billion A Year at Forbes
12:02PM  Regeneron Beats on Q4 Earnings Driven by Eylea Sales (revised) - Analyst Blog Zacks
07:10AM  Predictive analytics firm RapidMiner raises $15M; breaks into Internet of Things market at American City Business Journals
Feb-17-15 04:59PM  CVS girds for battle over cholesterol drugs at MarketWatch
11:31AM  ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (eliglustat) for Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association Business Wire
Feb-12-15 05:37PM  Stock Therapy: Hedge funds target biotech CNBC
04:15PM  Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Networks WORLD Symposium 2015 Business Wire
02:35PM  Dyax aims at preventative treatment for rare swelling disease at American City Business Journals
08:45AM  Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga® (eliglustat) at Lysosomal Disease Networks WORLD Symposium 2015 Business Wire
Feb-11-15 02:03PM  Genzyme's $845M pact with Voyager will advance gene therapy at American City Business Journals
08:27AM  Sanofi -- Moodys: Low growth rates expected for 2015 EMEA Pharma companies at Moody's
Feb-10-15 05:43PM  Unilife's unique delivery systems CNBC
04:38PM  Regeneron Earnings Growth Falls Short, But Eylea Sales, '15 Outlook Are Solid Investor's Business Daily
02:40PM  Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog Zacks
11:01AM  Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea at Investor's Business Daily
09:28AM  Regeneron Beats on Q4 Earnings Driven by Eylea Sales - Analyst Blog Zacks
Feb-09-15 07:00AM  Sanofi (SNY): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Feb-06-15 10:25AM  Lexington-based Synta to cut 20 percent of workforce and consolidate lab space at American City Business Journals
09:04AM  Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog Zacks
Feb-05-15 07:49AM  Sanofi Delivers Business EPS Growth of 7.3% at CER in 2014 PR Newswire
06:39AM  European Stocks Move Lower as ECB Won't Accept Greek Bonds at TheStreet
02:14AM  Sanofi FY 2014 - Interview With Chairman & CEO Serge Weinberg PR Newswire
Feb-04-15 04:39PM  Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog Zacks
Feb-03-15 07:01PM  Bleaker Future for Men With Prostate Cancer This World Cancer Day PR Newswire
07:00AM  Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. PR Newswire
Jan-30-15 10:00PM  SANOFI 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Sanofi - SNY Marketwired
03:16PM  Moody's Downgrades Three and Affirms Nine Classes of GCCFC 2006-GG7 at Moody's
08:59AM  Diabetics: Use Your Firsthand Experience To Beat Wall Street at Forbes
Jan-29-15 09:08AM  UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015 -- SNY GlobeNewswire
Jan-28-15 10:32AM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Sanofi Business Wire
Jan-27-15 06:50PM  Regeneron/Sanofi's PCSK9 Drug Gets FDA Priority Review - Analyst Blog Zacks
03:30PM  Afrezza Breathes Life Into MannKind at Forbes
Jan-26-15 02:46AM  Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race at Forbes
01:00AM  Regeneron and Sanofi Announce Praluent (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA PR Newswire
Jan-23-15 04:00PM  Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog Zacks
Jan-22-15 07:07PM  UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Sanofi SA and a Lead Plaintiff Deadline of February 2, 2015 GlobeNewswire
09:24AM  5 Big Stocks to Trade for Gains: Cisco, Sanofi and More at TheStreet
01:00AM  European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzymes Oral Therapy for Gaucher Disease Type 1 Business Wire
Jan-21-15 06:15PM  Amicus Therapeutics CEO: Driving science to a cure CNBC
08:19AM  The Promise Of Financial Return Is Driving Both The "Biotech Bubble" And Orphan Drugs at Forbes
07:00AM  The BBJ's Five Things: Vertex's big moment; Nurses unite; Top home sales; Alnylum cashes in at American City Business Journals
Jan-20-15 10:01PM  ALERT: Rosen Law Firm Reminds Sanofi Investors of Important February 2, 2015 Class Action Deadline - SNY GlobeNewswire
10:00PM  SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sanofi -- SNY GlobeNewswire
06:32PM  INVESTOR ALERT: Class Action Lawsuit Against Sanofi Announced by Law Offices of Howard G. Smith Business Wire
06:12PM  Evotec Signs New Deal for Addictive Disorder Therapies - Analyst Blog Zacks
03:30PM  Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst Blog Zacks
01:00PM  With $450M sale, Alnylam has more cash than any pre-commercial biotech at American City Business Journals
Jan-19-15 06:00PM  Making Money With Charles Payne: 01/19/15 at Fox Business
03:59PM  UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015 Business Wire
05:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sanofi of Class Action Lawsuit and Upcoming Deadline -- SNY GlobeNewswire
Jan-16-15 10:00PM  Sanofi Shareholder Alert by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sanofi Business Wire
Jan-14-15 12:32PM  INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sanofi Business Wire
12:11PM  SNY SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015 Business Wire
Jan-12-15 04:21PM  Lieff Cabraser Reminds Sanofi Investors of Upcoming Deadline in Class Action Litigation - SNY Business Wire
03:44PM  Why The New MannKind Management Could Focus On R&D, Not A Potential Sanofi Merger Benzinga
01:35PM  MannKind Gets Little Love From Sanofi at 'JPM15' Presentation at TheStreet
01:00AM  Regeneron and Sanofi Announce Praluent (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA PR Newswire
Jan-09-15 04:41PM  A volatile end to a very volatile week... Yahoo Finance Blogs
04:30PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Sanofi To Contact Brower Piven Before The February 2, 2015 Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
03:42PM  Regeneron Jumps On Favorable Cholesterol Drug Report at Investor's Business Daily
01:58PM  Regeneron Can Generate 25% Upside for Investors at Barrons.com
12:32PM  INVESTOR ALERT: Class Action Lawsuit Against Sanofi Announced by Glancy Binkow & Goldberg LLP Business Wire
01:00AM  Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia PR Newswire
Jan-06-15 09:02PM  SHAREHOLDER ALERT: Investigation on Behalf of Investors of Sanofi Announced by Law Offices of Howard G. Smith Business Wire
Jan-02-15 10:00PM  SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Sanofi Business Wire
01:02PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015 -- SNY Marketwired
08:00AM  Shareholder Alert: Pomerantz Law Firm Announces the Filing of a Class Action against Sanofi and Certain Officers - SNY PR Newswire
Dec-31-14 12:03PM  The next great investing columnist looks back and ahead at MarketWatch
Dec-30-14 06:32PM  INVESTOR ALERT: Investigation on Behalf of Investors of Sanofi Announced by Glancy Binkow & Goldberg LLP Business Wire
01:50PM  Keryx drug for dialysis patients poised to challenge Genzyme at bizjournals.com
Dec-29-14 03:57PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sanofi SA and Its Board of Directors and a Lead Plaintiff Deadline of February 2, 2015 -- SNY GlobeNewswire
Dec-26-14 02:39PM  Why Bribing Lizard Squad To Stop Attacking Xbox Live And PSN Is A Terrible Idea at Forbes
Dec-24-14 09:07PM  Quick Update: New Hires, Recent Panel Discussion Emphasize Confluence Of Pharma And Big Data at Forbes
Dec-22-14 09:00AM  Lieff Cabraser Announces Class Action Litigation Against Sanofi SNY Business Wire
Dec-21-14 08:25PM  EQUITY ALERT: Rosen Law Firm Reminds Sanofi Investors of Important Class Action Deadline - SNY GlobeNewswire
Dec-20-14 10:00PM  SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sanofi -- SNY GlobeNewswire
Dec-19-14 05:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sanofi of Class Action Lawsuit and Upcoming Deadline -- SNY GlobeNewswire
Dec-18-14 12:08PM  5 Big Stocks to Trade After the Fed's Rate News: Microsoft, Goldman and More at TheStreet
Dec-17-14 07:06PM  Cramer Remix: Here's what the Fed did today at CNBC
Sanofi discovers, develops, and distributes therapeutic solutions. Its primary products include Lantus and Apidra analogs of human insulin; Insuman insulin solutions and suspensions; Amaryl, a sulfonylurea; Lyxumia, a prandial GLP-1 receptor agonist; BGStar, iBGStar, and MyStar Extra blood glucose meters; Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme for mucopolysaccharidosis Type I; Aubagio for multiple sclerosis; and Lemtrada, a humanized monoclonal antibody. The company's products also comprise Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; Jevtana for prostate cancer; Thymoglobulin, an immuno-suppressive and immuno-modulating agent; Mozobil stem cell mobilizer; and Zaltrap recombinant fusion protein. In addition, it offers thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. Further, it provides Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements for pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has a strategic alliance with Illumina, Inc. to develop a next-generation sequencing based oncology test system. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM
Sanofi10% OwnerJul 15Buy314.92129,10040,656,17622,204,841Jul 17 05:50 PM
Sanofi10% OwnerJul 14Buy318.18150,00047,726,79722,075,741Jul 15 05:45 PM
Sanofi10% OwnerJul 11Buy315.41150,00047,311,83621,925,741Jul 15 05:45 PM
Sanofi10% OwnerJul 10Buy311.08175,00054,439,07321,775,741Jul 14 05:46 PM
Sanofi10% OwnerJul 09Buy308.27195,00060,112,31121,600,741Jul 10 05:45 PM
Sanofi10% OwnerJul 08Buy311.67153,00047,685,74321,405,741Jul 10 05:45 PM
Sanofi10% OwnerJul 07Buy312.90256,70080,320,79521,252,741Jul 08 05:42 PM
Sanofi10% OwnerJul 03Buy311.02100,00031,101,94620,996,041Jul 08 05:42 PM
Sanofi10% OwnerJul 02Buy307.25212,40065,259,55220,896,041Jul 03 06:00 PM
Sanofi10% OwnerJul 01Buy300.20212,40063,761,42120,683,641Jul 03 05:46 PM
Sanofi10% OwnerJun 30Buy282.54212,40060,010,47920,471,241Jul 01 05:39 PM
Sanofi10% OwnerJun 27Buy275.3850,00013,769,09220,258,841Jul 01 05:39 PM
Sanofi10% OwnerMay 19Buy300.04190,75157,233,71620,208,841May 21 05:02 PM
Sanofi10% OwnerMar 28Buy306.73306,94594,149,58320,018,090Mar 31 06:22 PM
Sanofi10% OwnerMar 27Buy311.01306,94595,463,96319,711,145Mar 31 06:21 PM
Sanofi10% OwnerMar 24Buy307.91306,94594,511,73418,790,310Mar 25 06:11 PM
Sanofi10% OwnerMar 21Buy321.22305,11598,008,22218,483,365Mar 25 06:10 PM
Sanofi10% OwnerMar 20Buy328.4157,95719,033,51118,178,250Mar 21 06:21 PM
Sanofi10% OwnerMar 19Buy327.899,7463,195,65118,120,293Mar 21 06:21 PM
Sanofi10% OwnerMar 17Buy328.5560,12819,755,23418,110,547Mar 18 06:58 PM
Sanofi10% OwnerMar 14Buy328.3655,58318,251,21518,050,419Mar 18 06:58 PM
Sanofi10% OwnerMar 12Buy334.69220,99573,964,41217,994,836Mar 14 05:11 PM
Sanofi10% OwnerMar 11Buy332.26180,71060,043,33617,773,841Mar 12 05:36 PM
Sanofi10% OwnerMar 10Buy328.73199,82265,687,43517,593,131Mar 12 05:36 PM
Sanofi10% OwnerMar 07Buy332.51241,81880,405,73317,393,309Mar 10 09:52 PM
Sanofi10% OwnerMar 07Buy316.2069,87322,093,65517,151,491Mar 10 09:51 PM
Sanofi10% OwnerMar 06Buy339.6080,40427,305,54617,081,618Mar 10 09:51 PM
Sanofi10% OwnerMar 03Buy338.12251,59485,070,11817,001,214Mar 05 08:36 PM